Clinical Trial Update: Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II) [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating Y-90 labeled Fibroblast Activation Protein Inhibitor therapy in patients with non-small cell lung cancer, currently not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Y-90 Fibroblast Activation Protein Inhibitor Therapy (Fibroblast Activation Protein Inhibitor (FAPI) therapy labeled with Yttrium-90)

Snippet

Sponsor: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization | Conditions: Non-Small Cell Lung Cancer, Metastatic Lung Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING